Bexsero
- 1 February 2012
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (2) , 174-183
- https://doi.org/10.4161/hv.18500
Abstract
Serogroup B meningococcal (MenB) disease remains a serious public health problem for which a cross-protective vaccine effective against a wide range of MenB isolates has not been available. Novartis Vaccines has developed a vaccine for the prevention of MenB disease that contains four antigenic components: factor H binding protein (fHbp), neisserial adhesin A (NadA), Neisseria heparin binding antigen (NHBA) and outer membrane vesicles from a New Zealand epidemic strain (which provides PorA). This vaccine has been submitted for regulatory review in Europe so it is timely to review the design of the vaccine, results to date in clinical studies and the potential strain coverage provided by the vaccine. It is also critical to discuss the key issues for the long-term success of the vaccine which include strain coverage, potential persistence of protection, potential effects on carriage of MenB strains, potential for escape mutants and cost effectiveness.Keywords
This publication has 59 references indexed in Scilit:
- Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigenVaccine, 2011
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccinesProceedings of the National Academy of Sciences, 2010
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humansProceedings of the National Academy of Sciences, 2010
- Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolatesVaccine, 2009
- The modular architecture of meningococcal factor H-binding proteinMicrobiology, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Neisseria meningitidis recruits factor H using protein mimicry of host carbohydratesNature, 2009
- Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd ImmunityThe Journal of Infectious Diseases, 2008
- Prevalence of Factor H–Binding Protein Variants and NadA among Meningococcal Group B Isolates from the United States: Implications for the Development of a Multicomponent Group B VaccineThe Journal of Infectious Diseases, 2007
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences, 2006